What Is Drug-Induced Gigantomastia
Drug-induced gigantomastia is rapid, excessive breast growth linked to systemic medications, not puberty or pregnancy. It is rare, but documented case series show it can cause pain, skin ulceration, and functional impairment. The condition is often reversible if the offending drug is identified and stopped early, though surgery may be needed for severe tissue overgrowth. Review data on drug-induced gigantomastia.
Common drug classes include antipsychotics, antidepressants, hormonal therapies, and certain antibiotics. Prolactin elevation from medications like risperidone and other dopamine antagonists is a leading mechanism. Estrogenic compounds, including some fertility treatments and oral contraceptives, can also trigger diffuse glandular hyperplasia. FDA adverse event data lists hundreds of suspect reports tied to these drug classes.
Clinical Presentation and Diagnostic Criteria
Patients typically present with bilateral, rapid breast enlargement over weeks to months, often accompanied by tenderness, venous distension, and skin stretching. Physical exam reveals firm, diffuse glandular enlargement without discrete masses, distinguishing it from typical fibroadenomas or cysts. Mayo Clinic explains breast tissue overgrowth signs.
Diagnosis relies on clinical history, medication review, and imaging such as ultrasound or MRI to rule out malignancy. Serum prolactin, estrogen, and androgen levels help identify endocrine triggers. Biopsy is reserved for atypical presentations or suspected malignancy, showing benign stromal and epithelial proliferation without atypia. StatPearls outlines diagnostic approach.
Treatment Options and Outcomes
First-line management is discontinuation or substitution of the causative drug under physician supervision. Symptomatic relief often follows within weeks, but established hypertrophy may require reduction mammaplasty. Mayo Clinic details breast reduction surgery.
Corticosteroids, tamoxifen, and dopamine agonists are used in refractory cases to reduce inflammation or prolactin-driven growth. Surgical outcomes are generally favorable, with low recurrence when the offending agent is avoided. Long-term follow-up focuses on monitoring for relapse and managing psychological impact. Recent clinical review on management strategies.